GARY W. PACE - 11 May 2023 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Role
Director
Signature
/s/ Kristen Williams, Attorney-in-Fact
Issuer symbol
PCRX
Transactions as of
11 May 2023
Net transactions value
-$227
Form type
4
Filing time
15 May 2023, 18:53:06 UTC
Previous filing
19 Sep 2022
Next filing
16 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCRX Common Stock Options Exercise $209,300 +7,000 +5.1% $29.90 144,690 11 May 2023 Direct
transaction PCRX Common Stock Sale $209,527 -5,015 -3.5% $41.78 139,675 11 May 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCRX Stock Option (Right to Buy) Options Exercise $0 -7,000 -100% $0.000000* 0 11 May 2023 Common Stock 7,000 $29.90 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.75 to $41.85, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2 The stock option vested and became exercisable in twelve equal monthly installments, with the first installment being on July 12, 2013.